Panoset 0.5 mg (Tablet)

Title

• Panoset

Categories

• Medicine
• Pharmaceuticals
• Anti-emetic drugs

Description

• Panoset is indicated for acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, post-operative & post-discharge nausea and vomiting. It is a 5-HT3 receptor antagonist with linear dose-proportional pharmacokinetics and exhibits a longer half-life and greater 5-HT3 receptor binding affinity. The usual adult dosage for tablets is 0.5 mg daily and for IV administration is 0.075 mg over 10 seconds. It can be administered with corticosteroids, analgesics, antiemetics, antispasmodics, and anticholinergic agents without significant interactions. Palonosetron is contraindicated in patients with hypersensitivity to the drug or its components. The most common adverse reactions are headaches and constipation. It has a pregnancy category 'B' and use in elderly patients, children, and patients with impaired renal and hepatic function does not require dosage adjustment. There is no known antidote to Panoset, and overdose should be managed with supportive care. It belongs to the therapeutic class of anti-emetic drugs and should be stored in a cool and dry place, protected from light.

Color Options

• None

Dimensions

• Standard medicine tablet size

Functions

• Prevention and treatment of nausea and vomiting

Materials

• Active ingredient: Palonosetron

Technical Specifications

• Linear dose-proportional pharmacokinetics
• Longer half-life
• Greater 5-HT3 receptor binding affinity

Design Elements

• Tablet form
• IV administration

Usability Features

• Usual adult dosage: 0.5 mg daily for tablets, 0.075 mg over 10 seconds for IV administration
• Can be administered with other medications without significant interactions
• No dosage adjustment required for elderly patients, children, and patients with impaired renal and hepatic function

Dosage and Administration

• Usual adult tablet dosage: 0.5 mg daily
• Usual adult IV dosage: 0.075 mg over 10 seconds
• Children dosage: single IV dose at 20 mcg/kg body weight with a maximum dose of 1.5 mg
• Specific dosages for chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting

Interaction

• Can be safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents
• No significant pharmacokinetic interactions with metoclopramide
• Low potential for clinically significant drug interactions

Indications

• Indicated for acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, post-operative & post-discharge nausea and vomiting

Contraindications

• Contraindicated in patients known to have hypersensitivity to the drug or any of its components

Side Effects

• The most common adverse reactions are headaches and constipation

Pregnancy & Lactation

• Pregnancy category 'B'
• Excretion in breast milk not known

Use in Special Populations

• No dosage adjustment recommended in elderly patients >65 years of age
• Children dosage: single IV dose at 20 mcg/kg body weight with a maximum dose of 1.5 mg
• No dosage adjustment recommended in patients with impaired renal and hepatic function

Overdose Effects

• No known antidote to Panoset
• Overdose should be managed with supportive care

Therapeutic Class

• Anti-emetic drugs

Storage Conditions

• Store in a cool & dry place, protected from light

Related Brands

• Paloron 0.075 mg/1.5 ml (IV Injection) - ziska-pharmaceuticals-ltd
• Paloron 0.25 mg/5 ml (IV Injection) - ziska-pharmaceuticals-ltd
• Paloron 0.5 mg (Tablet) - ziska-pharmaceuticals-ltd
• Paloxi 0.5 mg (Capsule) - beacon-pharmaceuticals-plc
• Paloxi 0.075 mg/1.5 ml (IV Injection) - beacon-pharmaceuticals-plc